A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
NCT: NCT06469710 · RECRUITING
Brief Summary
The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients. The main questions it aims to answer are: 1. The advantages and disadvantages of two sampling methods for further diagnosis and treatment; 2. How to obtain further information on the tumour biology of CTC; 3. The mechanisms of prostate cancer invasion and metastasis Participants will have 7.5mL of peripheral blood taken as well as undergo leukapheresis.
Frequently Asked Questions
What is A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients?
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients is a clinical trial registered under NCT06469710. Current status: RECRUITING.
What is the status of NCT06469710?
The current status of NCT06469710 (A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients) is: RECRUITING.
When did A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients start?
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients started on 2024-06-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.